Comparison of Circulating Levels of Interleukin-6 and Tumor Necrosis Factor-alpha in Hypertrophic Cardiomyopathy and in Idiopathic Dilated Cardiomyopathy
Overview
Affiliations
It is known from the literature that the circulating levels of tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) are elevated in heart failure and idiopathic dilated cardiomyopathy (IDC). Few convincing data are available on the production of cytokines in hypertrophic cardiomyopathy (HC). The levels of circulating IL-6, the soluble form of the IL-6 receptor (sIL-6R), and TNF-alpha in 19 patients with HC, 31 patients with IDC, and 20 healthy subjects (control group) were examined and compared with their clinical parameters. The levels of TNF-alpha and circulating IL-6 proved to be elevated in the sera of patients with IDC. In contrast, the level of TNF-alpha was not elevated in HC, although the levels of IL-6 and sIL-6R were significantly higher than those in the sera of patients with IDC. Although elevated levels of IL-6 may correlate with the extent of left ventricular dysfunction in IDC, the markedly elevated IL-6 levels did not correlate with left ventricular function in HC. The markedly elevated TNF-alpha levels in IDC were associated with the elevated IL-6 levels, probably because of an inflammatory process and/or heart failure. In contrast, in HC, in which the New York Heart Association functional class was actually good, the even higher IL-6 and sIL-6R levels were not associated with a TNF-alpha elevation. In HC, the IL-6 and sIL-6R elevations were due to another mechanism, probably by way of the cardiotrophin-associated gp130 receptor. The sources of IL-6 production in HC are not clear yet.
Cytokeratin 18 as a Novel Biomarker in Patients with Hypertrophic Cardiomyopathy.
Fragkiadakis K, Ktena N, Kalantidou A, Dermitzaki E, Anastasiou I, Papathanassiou S Cells. 2024; 13(16.
PMID: 39195218 PMC: 11352956. DOI: 10.3390/cells13161328.
Gu J, Zhao Y, Ben Y, Zhang S, Hua L, He S Sci Rep. 2024; 14(1):17023.
PMID: 39043774 PMC: 11266364. DOI: 10.1038/s41598-024-67201-8.
Li L, Ban C, Ruan H, Zhang M, Wang Z, Ma M BMC Cardiovasc Disord. 2023; 23(1):559.
PMID: 37974066 PMC: 10652625. DOI: 10.1186/s12872-023-03562-8.
The Microenvironment of the Pathogenesis of Cardiac Hypertrophy.
Bazgir F, Nau J, Nakhaei-Rad S, Amin E, Wolf M, Saucerman J Cells. 2023; 12(13).
PMID: 37443814 PMC: 10341218. DOI: 10.3390/cells12131780.
Cytokine Pathways in Cardiac Dysfunction following Burn Injury and Changes in Genome Expression.
Dejesus J, Wen J, Radhakrishnan R J Pers Med. 2022; 12(11).
PMID: 36579591 PMC: 9696755. DOI: 10.3390/jpm12111876.